Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2-Reference-Cited by-同舟云学术

Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2

Published:2017-02-22 Issue:3 Volume:19 Page:161-172
ISSN:2156-8952
Container-title:ACS Combinatorial Science
language:en
Short-container-title:ACS Comb. Sci.

Author:

Barnash Kimberly D.¹,The Juliana²,Norris-Drouin Jacqueline L.¹,Cholensky Stephanie H.¹,Worley Beau M.¹,Li Fengling²,Stuckey Jacob I.¹,Brown Peter J.²,Vedadi Masoud²,Arrowsmith Cheryl H.²³,Frye Stephen V.¹,James Lindsey I.¹^ORCID

Affiliation:

1. Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

2. Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada

3. Princess Margaret Cancer Centre and Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2M9, Canada

Funder

National Institute of General Medical Sciences

University Cancer Research Fund, University of North Carolina at Chapel Hill

Publisher

American Chemical Society (ACS)

Subject

General Chemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acscombsci.6b00174

Reference39 articles.

1. Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

2. The polycomb group protein EZH2 is involved in progression of prostate cancer

3. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

4. The Murine Polycomb Group Protein Eed Is Required for Global Histone H3 Lysine-27 Methylation

5. The Polycomb complex PRC2 and its mark in life

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical inhibitors targeting histone methylation readers;Pharmacology & Therapeutics;2024-04

2. Peptide-based inhibitors of epigenetic proteins;Progress in Molecular Biology and Translational Science;2024

3. Exploring the therapeutic potential of targeting polycomb repressive complex 2 in lung cancer;Frontiers in Oncology;2023-10-16

4. Recent advances in the development of peptide-based inhibitors targeting epigenetic readers of histone lysine acetylation and methylation marks;Current Opinion in Chemical Biology;2023-08

5. The roles of EZH2 in cancer and its inhibitors;Medical Oncology;2023-05-06